Mereo BioPharma Group plc MAH0.SG Stock
Mereo BioPharma Group plc Price Chart
Mereo BioPharma Group plc MAH0.SG Financial and Trading Overview
Mereo BioPharma Group plc stock price | 2.55 EUR |
Previous Close | 1.22 EUR |
Open | 1.24 EUR |
Bid | 1.24 EUR x N/A |
Ask | 1.35 EUR x N/A |
Day's Range | 1.24 - 1.24 EUR |
52 Week Range | 0.46 - 1.84 EUR |
Volume | 0 EUR |
Avg. Volume | 1.24K EUR |
Market Cap | 162.49M EUR |
Beta (5Y Monthly) | 0.838849 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.19 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
MAH0.SG Valuation Measures
Enterprise Value | 103.63M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 2.5 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -2.386 |
Trading Information
Mereo BioPharma Group plc Stock Price History
Beta (5Y Monthly) | 0.838849 |
52-Week Change | -8.95% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.84 EUR |
52 Week Low | 0.46 EUR |
50-Day Moving Average | 0.95 EUR |
200-Day Moving Average | 0.87 EUR |
MAH0.SG Share Statistics
Avg. Volume (3 month) | 1.24K EUR |
Avg. Daily Volume (10-Days) | 61 EUR |
Shares Outstanding | 124.99M |
Float | 79.28M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 51.67% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -25.39% |
Return on Equity (ttm) | -45.63% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 936K EUR |
EBITDA | -43425000 EUR |
Net Income Avi to Common (ttm) | -34196000 EUR |
Diluted EPS (ttm) | -0.37 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 56.33M EUR |
Total Cash Per Share (mrq) | 0.45 EUR |
Total Debt (mrq) | 12.77M EUR |
Total Debt/Equity (mrq) | 20.65 EUR |
Current Ratio (mrq) | 2.518 |
Book Value Per Share (mrq) | 0.496 |
Cash Flow Statement
Operating Cash Flow (ttm) | -38820000 EUR |
Levered Free Cash Flow (ttm) | -22523750 EUR |
Profile of Mereo BioPharma Group plc
Country | Germany |
State | N/A |
City | London |
Address | One Cavendish Place |
ZIP | W1G 0QF |
Phone | 44 33 3023 7300 |
Website | https://www.mereobiopharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 36 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Q&A For Mereo BioPharma Group plc Stock
What is a current MAH0.SG stock price?
Mereo BioPharma Group plc MAH0.SG stock price today per share is 2.55 EUR.
How to purchase Mereo BioPharma Group plc stock?
You can buy MAH0.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mereo BioPharma Group plc?
The stock symbol or ticker of Mereo BioPharma Group plc is MAH0.SG.
Which industry does the Mereo BioPharma Group plc company belong to?
The Mereo BioPharma Group plc industry is Biotechnology.
How many shares does Mereo BioPharma Group plc have in circulation?
The max supply of Mereo BioPharma Group plc shares is 140.26M.
What is Mereo BioPharma Group plc Price to Earnings Ratio (PE Ratio)?
Mereo BioPharma Group plc PE Ratio is now.
What was Mereo BioPharma Group plc earnings per share over the trailing 12 months (TTM)?
Mereo BioPharma Group plc EPS is -0.19 EUR over the trailing 12 months.
Which sector does the Mereo BioPharma Group plc company belong to?
The Mereo BioPharma Group plc sector is Healthcare.